Chapter 41: Role of Sex Steroids in the Pathogenesis of Osteoporosis Matthew T. Drake and Sundeep Khosla.

Slides:



Advertisements
Similar presentations
Copyright © 2013 Elsevier Inc. All rights reserved.
Advertisements

Chapter 67 Chapter 67 Biochemical Markers of Bone Turnover in Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 31 Chapter 31 Clinical and Epidemiological Studies: Skeletal Changes across Menopause Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 77 Chapter 77 Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
How Should We Monitor, Prevent, and Treat Osteoporosis in IBD? All of Our IBD Patients are at Risk and Therefore all Should Begin Treatment at Diagnosis.
Physical Activity and Bone Health during Childhood and Adolescence: Critical Periods for the Prevention of Osteoporosis Suggested Links (click below)
Bone Quality PART 1 Introduction Architecture Turnover.
WHO Osteoporosis Definition (1996)
Bone Quality PART 3 Collagen/Mineral Matrix Conclusions Supplemental Slides.
Aging of the Skeleton: Osteoporosis An Evolutionary and Biocultural Perspective.
an underestimated disease
OSC Recommendations for Bone Mineral Density Reporting Slides prepared by Kerry Siminoski, MD, FRCPC William Leslie, M.Sc., MD,
Relationship of Drug Associated Change in Bone Mineral Density to Fracture Risk Marc C. Hochberg, MD, MPH FDA Endocrinologic and Metabolic Drugs Advisory.
Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.
OSTEOPOROSIS Prof. Dr. Ülkü Akarırmak. Metabolic Bone Diseases Osteosclerosis Osteolysis Osteoporosis is the most common metabolic bone disease.
ECTS symposium 5 Anabolic treatment of osteoporosis.
Hanna Przepiera-Będzak Klinika Reumatologii PAM, Szczecin.
Copyright © 2013 Elsevier Inc. All rights reserved.
Gaucher Disease: Bone Imaging. DXA (Dual-Energy X-ray Absorptiometry)
Chapter 83 Chapter 83 Denosumab for the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Internal Medicine Weekly Conference 1392 Internal Medicine Weekly Conference 1392 Alimohammad Fatemi Assistant Professor of Rheumatology Alimohammad Fatemi.
Pathogenesis of Osteoporotic Fracture LOW PEAK BONE MASS LOW PEAK BONE MASS POSTMENOPAUSAL BONE LOSS POSTMENOPAUSAL BONE LOSS AGE-RELATED BONE LOSS.
June 2004 Bone Quality Sourced from NIH Consensus Development Panel on Osteoporosis. JAMA 285: ; 2001 Architecture Turnover Rate Damage Accumulation.
T.S. Tran, J.R. Center, M.J. Seibel, J.A. Eisman,
Chapter 72 Chapter 72 Calcium in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 54 Chapter 54 HIV and Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
Osteoporosis Armed Forces Academy of Medical Sciences.
Osteoporosis. Background ► The problem  Osteoporosis is common  Over 50% of women and 30-45% of men over age 50 have osteopenia/osteoporosis  White.
Osteoporosis Dr Ramin Rafiei Alzahra Hospital Rheumatology Department.
Alimohammad Fatemi Assistant Professor of Rheumatology 1.
June 2004 Conclusion Slides. June 2004 Bone quality is an integral component of bone strength Maintaining or restoring bone architecture is required for.
Ten Years’ Experience with Alendronate for the Treatment of Osteoporosis in Postmenopausal Women Adapted from Bone HG, Hosking D, Devogelaer J-P, Tucci.
Prevention and Treatment of Osteoporosis
ANA Testing Carrie Marshall 1/18/08. Osteoporosis Epidemiology The Most Commom Metbolic Disease In The World In US Female>50: Osteoporosis=17% Osteopenia=
Chapter 7: Assessment of Bone Mass and Microarchitecture in Rodents Blaine A. Christiansen and Mary L. Bouxsein.
Date of download: 5/31/2016 From: Alendronate and Estrogen–Progestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal.
Chapter 47 Assessing Fracture Risk: Who Should Be Screened? © American Society for Bone and Mineral Research Contributed by John Schousboe, Brent Taylor,
Moji Saberin-Williams, M.D. Paoli Hospital Obstetrician/Gynecologist
Chapter 34: Biochemical Markers of Bone Turnover in Osteoporosis Pawel Szulc and Pierre D. Delmas.
Chapter 48 Evaluation of Postmenopausal Osteoporosis © American Society for Bone and Mineral Research Contributed by Susan Greenspan and Marjorie Luckey.
J Clin Endocrinol Metab, Sep 2006, 91(9):
Osteopenia and Osteoporosis
Chapter 29: DXA in Adults and Children Judith Adams and Nick Bishop.
Chapter 49: Bisphosphonates for Postmenopausal Osteoporosis
Chapter 62: Osteoporosis in Men
Volume 48, Issue 4, Pages (April 2011)
Chapter 68: Hypocalcemia: Definition, Etiology, Pathogenesis, Diagnosis, and Management Dolores Shoback.
OSTEOPOROSIS Florence TREMOLLIERES, MD, PhD
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis  Peyman Hadji  Critical Reviews in Oncology.
Chapter 38: Epidemiology of Osteoporotic Fractures
Chapter 61: Transplantation Osteoporosis
Chapter 45: Orthopedic Surgical Principles of Fracture Management
Chapter 50: Strontium Ranelate in the Prevention of Osteoporotic Fractures René Rizzoli.
Chapter 67: Non-Parathyroid Hypercalcemia
Figure 1. Serum B-ALP levels in normal male (•) and female (○) children as a function of age. Serum B-ALP levels were increased during infancy and puberty.
Chapter 55: Cost-Effectiveness of Osteoporosis Treatment
Figure 1. Height distribution for adults with AIS.
Chapter 60: Osteoporosis: Other Secondary Causes
Fig. 1. Trial profile. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the.
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Osteoporosis in Individuals with Spinal Cord Injury
History of the Rochester Epidemiology Project
The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy  Solomon Epstein, MD  Mayo.
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Treatment Options for Osteoporosis
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Yong-jiang Hei  European Urology Supplements 
Chapter 45 Osteoporosis in AdultsPhoto Album
Chapter 44 Osteoporosis: The Early Years
Volume 79, Issue 4, Pages (February 2011)
Presentation transcript:

Chapter 41: Role of Sex Steroids in the Pathogenesis of Osteoporosis Matthew T. Drake and Sundeep Khosla

Table 1: Spearman Correlation Coefficients Relating Rates of Change in BMD at the Radius and Ulna to Serum Sex Steroid Levels Among a Sample of Rochester, MN, Men Stratified by Age From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7 th Edition.

Figure 1 Figure 1 Patterns of age-related bone loss in women and men. Dashed lines, trabecular bone; solid lines, cortical bone. The figure is based on multiple cross-sectional and longitudinal studies using DXA. (Reprinted with permission from Elsevier from Khosla S, Riggs BL 2005 Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin North Am 34:1015–1030, Copyright 2005.) From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7 th Edition.

Figure 2 Figure 2 (A) Values for vBMD (mg/cm3) of the total vertebral body in a population sample of Rochester, MN, women and men between the ages of 20 and 97 yr. Thin-dashed line, premenopausal women; thick- dashed line, postmenopausal women; solid line, men. (B) Values for cortical vBMD at the distal radius in the same cohort. Line coding as in A. All changes with age were significant (p < 0.05). (Adapted with permission of the American Society for Bone and Mineral Research from Riggs BL, Melton LJI, Robb RA, Camp JJ, Atkinson EJ, Peterson JM, Rouleau PA, McCollough CH, Bouxsein ML, Khosla S 2004 Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res 19:1945–1954.) © 2008 American Society for Bone and Mineral Research From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7 th Edition.

Figure 3 Figure 3 Age-specific incidence rates for proximal femur (hip), vertebral (spine), and distal forearm (wrist) fractures in Rochester, MN, women (A) and men (B). (Adapted with permission from Elsevier from Cooper C, Melton LJ 1992 Epidemiology of osteoporosis. Trends Endocrinol Metab 3:224–229, Copyright 1992.) From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7 th Edition.

Figure 4 Figure 4 Percent changes in (A) bone resorption markers (urinary deoxypyridinoline [Dpd] and N- telopeptide of type I collagen [NTX]) and (B) bone formation markers (serum osteocalcin and N-terminal extension peptide of type I collagen [PINP]) in a group of elderly men (mean age, 68 yr) made acutely hypogonadal and treated with an aromatase inhibitor (group A), estrogen alone (group B), testosterone alone (group C), or both estrogen and testosterone (group D). Significance for change from baseline: *p < 0.05; **p < 0.01; ***p < (Adapted with permission from American Society for Clinical Investigation from Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S 2000 Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553–1560.(34)) From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7 th Edition.